Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004892 · ClinicalTrials.gov registry record · Phase 1
O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00004892: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00004892 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004892, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of O6-benzylguanine and implanted carmustine wafers in treating patients who have recurrent malignant glioma.
Interventions
- DRUG O6-benzylguanine
- PROCEDURE conventional surgery
- DRUG polifeprosan 20 with carmustine implant
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004892
The ClinicalTrials.gov registry entry for NCT00004892 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which O6-benzylguanine is the first listed.
NCT00004892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004892 about?
NCT00004892 is a clinical study titled "O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of O6-benzylguanine and implanted carm...
What is the current status of trial NCT00004892?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-04.
What interventions are being tested in trial NCT00004892?
The interventions under investigation include: O6-benzylguanine (DRUG), conventional surgery (PROCEDURE), polifeprosan 20 with carmustine implant (DRUG).
Who is sponsoring clinical trial NCT00004892?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.